Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy

NCT02403869 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 149

Last updated 2022-06-30

No results posted yet for this study

Summary

Post-authorization, prospective follow-up, multi-centre, national study to estimate definitive deterioration in the quality of life in patients with metastatic breast cancer treated with second-line monochemotherapy.

Conditions

  • Breast Neoplasms

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-12
Primary Completion
2019-01-31
Completion
2019-01-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02403869 on ClinicalTrials.gov